Price$9.37+0.19 (+2.07%)
01:30 PM07:45 PM
News · 26 weeks55+200%
2026-03-012026-08-23
Mix2390d
- SEC Filings9(39%)
- Insider8(35%)
- Other2(9%)
- Earnings2(9%)
- Leadership1(4%)
- Analyst1(4%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Arvinas Inc.SCHEDULE 13G/A - ARVINAS, INC. (0001655759) (Subject)
- SECSEC Form 144 filed by Arvinas Inc.144 - ARVINAS, INC. (0001655759) (Subject)
- SECSEC Form 10-Q filed by Arvinas Inc.10-Q - ARVINAS, INC. (0001655759) (Filer)
- ANALYSTArvinas downgraded by Wells FargoWells Fargo downgraded Arvinas from Overweight to Equal Weight
- SECArvinas Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ARVINAS, INC. (0001655759) (Filer)
- PRArvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update– Secured the first-ever regulatory approval of a PROTAC (a type of heterobifunctional protein degrader), VEPPANU, and successfully completed out-licensing to Rigel Pharmaceuticals – – Anticipates sharing clinical data from three Phase 1 programs - ARV-393, ARV-102 and ARV-027 - over the next 12 months – – Presented promising preclinical data for HPK1 degrader program (ARV-6723) demonstrating the potential to overcome immune checkpoint inhibitor resistance in solid tumors – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based
- PRArvinas to Report Second Quarter 2026 Financial Results on August 4, 2026NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review second quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, August 4, 2026 at 8:00 a.m. ET. The webcast can be accessed under "Events and Presentations" on the investor page of the Arvinas website. A replay of the webcast will be available on the Arvinas website at www.arvinas.com following the completion of the event. About Arvinas Arvinas (NASDAQ:ARVN) is a biotechnology company dedicated to improving the lives of patients suffe
- SECSEC Form 144 filed by Arvinas Inc.144 - ARVINAS, INC. (0001655759) (Subject)
- INSIDERDirector Smaldone Alsup Laurie was granted 15,527 shares, increasing direct ownership by 60% to 41,572 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERDirector Norwalk Leslie V was granted 15,527 shares, increasing direct ownership by 60% to 41,572 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERDirector Morrison Briggs was granted 15,527 shares, increasing direct ownership by 16% to 111,548 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERDirector Kennedy Edward Moore Jr. was granted 15,527 shares, increasing direct ownership by 39% to 54,957 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERDirector Cunningham Everett was granted 15,527 shares, increasing direct ownership by 60% to 41,572 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERDirector Bain Linda was granted 15,527 shares, increasing direct ownership by 60% to 41,572 units (SEC Form 4)4 - ARVINAS, INC. (0001655759) (Issuer)
- SECArvinas Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - ARVINAS, INC. (0001655759) (Filer)
- INSIDERChief Financial Officer Saik Andrew sold $46,474 worth of shares (5,696 units at $8.16), decreasing direct ownership by 3% to 187,432 units (SEC Form 4) (for withholding tax)4 - ARVINAS, INC. (0001655759) (Issuer)
- SECSEC Form 144 filed by Arvinas Inc.144 - ARVINAS, INC. (0001655759) (Subject)
- SECArvinas Inc. filed SEC Form 8-K: Leadership Update8-K - ARVINAS, INC. (0001655759) (Filer)
- INSIDERChief Scientific Officer Cacace Angela M sold $19,565 worth of shares (2,576 units at $7.60), decreasing direct ownership by 1% to 180,390 units (SEC Form 4) to satisfy withholding obligation4 - ARVINAS, INC. (0001655759) (Issuer)
- SECArvinas Inc. filed SEC Form 8-K: Other Events8-K - ARVINAS, INC. (0001655759) (Filer)
- PRArvinas Joins The Michael J. Fox Foundation's LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson's DiseaseNEW HAVEN, Conn., June 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced it has recently joined the LRRK2 Investigative Therapeutics Exchange (LITE) program and the Parkinson's Precision Medicine Initiative (PPMI), both supported by The Michael J. Fox Foundation for Parkinson's Research (MJFF). Participation in these programs will support advancement of ARV-102, Arvinas' investigational, orally bioavailable and brain-penetrant PROTAC designed to specifically target and degrade leucine-rich repeat kinase 2 (LRRK2) for the potential treatment of neurodegenerative diseases, in
- SECArvinas Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - ARVINAS, INC. (0001655759) (Filer)
- PRArvinas to Present at Jefferies Global Healthcare ConferenceNEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3 at 9:55 a.m. ET. A live audio webcast of the presentation will be available here and under "Events and Presentations" on the Investors and Media section of the Company's website. About ArvinasArvinas (NASDAQ:ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its P
- INSIDERPresident and CEO Teel Randy sold $19,962 worth of shares (2,209 units at $9.04), decreasing direct ownership by 0.77% to 285,009 units (SEC Form 4) (tax liability)4 - ARVINAS, INC. (0001655759) (Issuer)
- INSIDERChief Financial Officer Saik Andrew sold $110,693 worth of shares (11,139 units at $9.94), decreasing direct ownership by 5% to 193,128 units (SEC Form 4) to satisfy withholding obligation4 - ARVINAS, INC. (0001655759) (Issuer)
ARVN FAQ
7 questionsWhat does Arvinas Inc. do?
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The...Where does ARVN stock trade?
Arvinas Inc. (ARVN) is listed on NASDAQ.What sector and industry is ARVN in?
Arvinas Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Arvinas Inc. go public?
Arvinas Inc. (ARVN) completed its IPO in 2018.What are analysts saying about ARVN?
Arvinas Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Equal Weight on 2026-08-04. Recent price targets range from $600.00 to $1600.00.What companies are similar to ARVN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ARVN side-by-side with any of them on Quantisnow.How can I track ARVN on Quantisnow?
Quantisnow aggregates Arvinas Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARVN to receive live email and push alerts on every new disclosure.